Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen

Vaccine

Volumn 29, Issue 6, 2011, Pages 1258-1269

  Arias, Mauricio A ^a   Loxley, Andrew ^b   Eatmon, Christy ^b   Van Roey, Griet ^a   Fairhurst, David ^b   Mitchnick, Mark ^b   Dash, Philip ^a,d   Cole, Tom ^a   Wegmann, Frank ^c   Sattentau, Quentin ^c   Shattock, Robin ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Particle Sciences Inc   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF READING   (United Kingdom)

Author keywords

Gp140 antigen; HIV; Mucosal immunity; Nanoparticles; Vaccines

Indexed keywords

CARNAUBA WAX; CHEMOKINE; CYTOKINE; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NANOPARTICLE; TETANUS TOXOID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; WAX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSA CELL; NONHUMAN; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELL PROLIFERATION; DENDRITIC CELLS; DRUG CARRIERS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NANOPARTICLES; T-LYMPHOCYTES; VAGINA; WAXES;

EID: 78751581822     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.084     Document Type: Article

References (52)

1. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development 1. Nat Rev Immunol 2010, 10(January (1)):11-23.
2. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006, 6(December (2)):930-939.
3. HIV gp120 vaccine VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDS. Drugs R D 2003, 4(4):249-253.
4. Bradac J., Dieffenbach C.W. HIV vaccine development: lessons from the past, informing the future. IDrugs 2009 Jul, 12(7):435-439.
5. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22(January 30 (3)):339-348.
6. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(December 3 (23)):2209-2220.
7. Shattock R.J., Haynes B.F., Pulendran B., Flores J., Esparza J. Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 2008, 5(April 1 (4)):e81.
8. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(January (1)):23-32.
9. Chellat F., Merhi Y., Moreau A., Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005, 26(December (35)):7260-7275.
10. Copland M.J., Baird M.A., Rades T., McKenzie J.L., Becker B., Reck F., et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003, 21(February 14 (9-10)):883-890.
11. Kempf M., Mandal B., Jilek S., Thiele L., Voros J., Textor M., et al. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles. J Drug Target 2003, 11(January (1)):11-18.
12. Singh M., Kazzaz J., Ugozzoli M., Chesko J., O'Hagan D.T. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther 2004, 4(April (4)):483-491.
13. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178(March 1 (5)):2979-2986.
14. Wischke C., Borchert H.H., Zimmermann J., Siebenbrodt I., Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006, 114(September 12 (3)):359-368.
15. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117(January (1)):78-88.
16. Tobio M., Nolley J., Guo Y., McIver J., Alonso M.J. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm Res 1999, 16(May (5)):682-688.
17. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 2004, 93(February (2)):273-282.
18. Westwood A., Healey G.D., Williamson E.D., Eyles J.E. Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen. Vaccine 2005, 23(May 31 (29)):3857-3863.
19. Akagi T., Kawamura M., Ueno M., Hiraishi K., Adachi M., Serizawa T., et al. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 2003, 69(February (2)):163-172.
20. Aline F., Brand D., Pierre J., Roingeard P., Severine M., Verrier B., et al. Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine 2009, 27(August 20 (38)):5284-5291.
21. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 2000, 67(July 3 (2-3)):347-356.
22. Wang X., Uto T., Akagi T., Akashi M., Baba M. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 2007, 81(September (18)):10009-10016.
23. Su L., Graf M., Zhang Y., von B.H., Xing H., Kostler J., et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 2000, 74(December (23)):11367-11376.
24. Biancotto A., Grivel J.C., Iglehart S.J., Vanpouille C., Lisco A., Sieg S.F., et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1 2. Blood 2007, 109(May 15 (10)):4272-4279.
25. Chesko J., Kazzaz J., Ugozzoli M., O'Hagan D.T., Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. J Pharm Sci 2005, 94(November (11)):2510-2519.
26. Henderson R.A., Watkins S.C., Flynn J.L. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997, 159(July 15 (2)):635-643.
27. Gupta R.K., Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects 2. Vaccine 1995, 13(October (14)):1263-1276.
28. Do T.Q., Moshkani S., Castillo P., Anunta S., Pogosyan A., Cheung A., et al. Lipids including cholesteryl linoleate and cholesteryl arachidonate contribute to the inherent antibacterial activity of human nasal fluid 1. J Immunol 2008, 181(September 15 (6)):4177-4187.
29. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants 1. Curr Opin Immunol 2009, 21(February (1)):23-29.
30. Singh M., Kazzaz J., Ugozzoli M., Malyala P., Chesko J., O'Hagan D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv 2006, 3(January (1)):115-120.
31. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res 2004, 21(December (12)):2148-2152.
32. Bekeredjian-Ding I., Jego G. Toll-like receptors - sentries in the B-cell response. Immunology 2009, 128(November (3)):311-323.
33. Kool M., Soullie T., van N.M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205(April 14 (4)):869-882.
34. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181(July 1 (1)):17-21.
35. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009, 106(January 20 (3)):870-875.
36. Harandi A.M., Medaglini D., Shattock R.J. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010, 28(March 11 (12)):2363-2366.
37. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
38. Lai S.K., Wang Y.Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61(February 27 (2)):158-171.
39. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl.)):S45-S53.
40. Kunkel E.J., Butcher E.C. Plasma-cell homing. Nat Rev Immunol 2003, 3(October (10)):822-829.
41. Brooking J., Davis S.S., Illum L. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 2001, 9(4):267-279.
42. Davis I.C., Owen R.L. The immunopathology of M cells. Springer Semin Immunopathol 1997, 18(4):421-448.
43. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000, 436(June (6)):560-566.
44. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002, 168(March 15 (6)):2930-2938.
45. Bradney C.P., Sempowski G.D., Liao H.X., Haynes B.F., Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002, 76(January (2)):517-524.
46. Hirano T., Jiao X., Chen Z., Van W.C., Gu X.X. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol Lett 2006, 107(November 15 (2)):131-139.
47. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003, 170(January 1 (1)):495-502.
48. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11(July (1)):1-18.
49. Vila A., Sanchez A., Evora C., Soriano I., McCallion O., Alonso M.J. PLA-PEG particles as nasal protein carriers: the influence of the particle size. Int J Pharm 2005, 292(March 23 (1-2)):43-52.
50. Caputo A., Castaldello A., Brocca-Cofano E., Voltan R., Bortolazzi F., Altavilla G., et al. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine 2009, 27(June 2 (27)):3605-3615.
51. Bielinska A.U., Janczak K.W., Landers J.J., Markovitz D.M., Montefiori D.C., Baker J.R. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008, 24(February (2)):271-281.
52. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79(June (11)):7059-7067.